Molecular Partners AG (MOLN) stock
MOLNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$2.94−0.07 (-2.33%)
Close on Nov 13, 2026Market cap $118.70MP/E –Yield –
Molecular Partners operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
For fiscal 2025 it was -CHF 58.12M. The highest annual figure on record is CHF 116.61M in fiscal 2022.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -CHF 58.12M | – |
| FY2024 | Dec 31, 2024 | -CHF 61.22M | – |
| FY2023 | Dec 31, 2023 | -CHF 61.11M | -152.4% |
| FY2022 | Dec 31, 2022 | CHF 116.61M | – |
| FY2021 | Dec 31, 2021 | -CHF 63.42M | – |
| FY2020 | Dec 31, 2020 | -CHF 58.33M | – |
| FY2019 | Dec 31, 2019 | -CHF 36.66M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -CHF 13.59M | – |
| Q2 FY2025 | Jun 30, 2025 | -CHF 17.32M | – |
| Q2 FY2024 | Jun 30, 2024 | -CHF 15.98M | – |
| Q2 FY2023 | Jun 30, 2023 | -CHF 15.88M | – |
| Q2 FY2022 | Jun 30, 2022 | -CHF 6.29M | – |
See a number that looks wrong?